[Pathophysiology and treatment of large granular lymphocyte leukemia-associated pure red cell aplasia].
Fujishima
Naohito
N
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D001803:Blood Transfusion; D003520:Cyclophosphamide / Q000008:administration & dosage; D016572:Cyclosporine / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D054066:Leukemia, Large Granular Lymphocytic / Q000150:complications* / Q000628:therapy*; D012010:Red-Cell Aplasia, Pure / Q000209:etiology* / Q000628:therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D000069283:Rituximab; D016572:Cyclosporine; D003520:Cyclophosphamide